for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adverum Biotechnologies Inc

ADVM.OQ

Latest Trade

11.57USD

Change

0.39(+3.49%)

Volume

340,644

Today's Range

11.06

 - 

11.64

52 Week Range

2.81

 - 

16.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Adverum Biotechnologies Reports Q3 Loss Per Share Of $0.25

Nov 7 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.25.Q3 REVENUE $300,000.Q3 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.Q3 REVENUE ESTIMATE $177,000 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $162.0 MILLION AS OF SEPTEMBER 30, 2019.

Adverum Biotechnologies Q2 Loss Per Share $0.23

Aug 8 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.

Adverum Biotechnologies Provides Update On Optic Phase 1 Trial For Advm-022 In Wet AMD

May 16 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES PROVIDES UPDATE ON OPTIC PHASE 1 TRIAL FOR ADVM-022 IN WET AMD.ADVERUM BIOTECHNOLOGIES INC - U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS LIFTED CLINICAL HOLD ON ADVM-022.ADVERUM BIOTECHNOLOGIES - FDA LIFTED CLINICAL HOLD ON SECOND COHORT, ADVM-022 REMAINS ON PARTIAL CLINICAL HOLD FOR DOSING PATIENTS IN THIRD COHORT.ADVERUM BIOTECHNOLOGIES INC - ADVERUM WILL CONTINUE TO WORK CLOSELY WITH FDA TO RESOLVE REMAINING CMC COMMENTS..

Adverum Biotechnologies Reports Q1 Loss Per Share $0.23

May 8 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.EXPECTS QUARTER-END CASH POSITION TO FUND OPERATIONS INTO 2021..ADVERUM EXPECTS THIS QUARTER-END CASH POSITION TO FUND OPERATIONS INTO 2021.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $189.5 MILLION AS OF MARCH 31, 2019.

Adverum Biotechnologies Announces Board Changes

May 2 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES ANNOUNCES BOARD CHANGES.ADVERUM BIOTECHNOLOGIES INC - PATRICK MACHADO APPOINTED AS BOARD CHAIR; PAUL CLEVELAND RETIRES FROM BOARD.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DIRECTORS REKHA HEMRAJANI, JAMES SCOPA AND MARK LUPHER ADDED TO BOARD.ADVERUM BIOTECHNOLOGIES INC - BOARD CONSISTS OF NINE DIRECTORS, EIGHT OF WHOM ARE INDEPENDENT.

Adverum Biotechnologies Provides Clinical Program Update On Advm-022 Gene Therapy For Wet AMD

April 15 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES PROVIDES CLINICAL PROGRAM UPDATE ON ADVM-022 GENE THERAPY FOR WET AMD.ADVERUM BIOTECHNOLOGIES INC - CLINICAL HOLD UNTIL ADDITIONAL CMC INFORMATION IS REVIEWED BY FDA.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DMC REVIEW OF SAFETY DATA FROM FIRST COHORT OF SIX PATIENTS WITH NO SAES OR DLTS.ADVERUM BIOTECHNOLOGIES INC - ADVERUM PLANS TO PRESENT 24-WEEK DATA FROM FIRST COHORT OF PATIENTS AT SCIENTIFIC MEETING IN 2H19.ADVERUM BIOTECHNOLOGIES - INDEPENDENT DATA MONITORING COMMITTEE (DMC) DETERMINED THAT ENROLLMENT AND DOSING OF PATIENTS IN SECOND COHORT COULD PROCEED.ADVERUM - RECEIVED NOTIFICATION FROM FDA IN EARLY APRIL REQUESTING ADDITIONAL CMC INFORMATION AND REQUIREMENTS ON ADVM-022 MANUFACTURING PROCESS.ADVERUM BIOTECHNOLOGIES INC - FDA HAS PLACED COMPANY'S IND ON CLINICAL HOLD UNTIL AGENCY HAS REVIEWED ADVERUM'S RESPONSE.

Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results

March 6 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.25.Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.EXPECTS YEAR-END CASH POSITION TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURES INTO 2021.ON TRACK TO PROVIDE AN ENROLLMENT UPDATE IN FIRST HALF OF 2019 ON OPTIC PHASE 1 CLINICAL TRIAL OF ADVM-022.ADVERUM BIOTECHNOLOGIES - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $205.1 MILLION AS OF DEC 31, 2018 VERSUS $217.9 MILLION AS OF SEPT 30, 2018.QTRLY REVENUE, CONSISTING OF REVENUE FROM COLLABORATIVE RESEARCH, WAS $0.1 MILLION VERSUS $0.5 MILLION.

Adverum Biotechnologies Provides 2019 Outlook

Jan 6 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES PROVIDES 2019 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $217.9 MILLION AS OF SEPTEMBER 30, 2018.ADVERUM BIOTECHNOLOGIES INC - ADVERUM EXPECTS THIS QUARTER-END CASH POSITION TO FUND OPERATIONS AT LEAST THROUGH FIRST HALF OF 2020.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE AN UPDATE ON ENROLLMENT FROM OPTIC PHASE 1 CLINICAL TRIAL IN FIRST HALF OF 2019.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE INTERIM DATA ON THREE COHORTS FROM OPTIC PHASE 1 CLINICAL TRIAL BY Q1 OF 2020.ADVERUM BIOTECHNOLOGIES INC - TO PROVIDE AN UPDATE ON RARE DISEASE PROGRAM'S PRECLINICAL DEVELOPMENT PLAN IN FIRST HALF OF 2019.

Adverum Biotechnologies Q3 Loss Per Share $0.34

Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.34.Q3 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.QTRLY COLLABORATION AND LICENSE REVENUE $833,000 VERSUS $463,000.Q3 REVENUE VIEW $380000.00 -- THOMSON REUTERS I/B/E/S.

Adverum Biotechnologies Announces Appointment Of Leone Patterson As CEO

Oct 17 (Reuters) - Adverum Biotechnologies Inc <ADVM.O>::ADVERUM BIOTECHNOLOGIES ANNOUNCES APPOINTMENT OF LEONE PATTERSON AS CEO AND MEMBER OF THE BOARD OF DIRECTORS.ADVERUM BIOTECHNOLOGIES - PATTERSON WILL CONTINUE TO SERVE AS CHIEF FINANCIAL OFFICER UNTIL A NEW CHIEF FINANCIAL OFFICER IS HIRED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up